Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease
Importance Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated
associations with positive kidney-related and cardiovascular outcomes in patients with type …
associations with positive kidney-related and cardiovascular outcomes in patients with type …
GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
HC Pan, JY Chen, HY Chen, FY Yeh, CY Sun… - Nature …, 2024 - nature.com
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 …
(GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 …
Enhanced Outcomes in Type 2 Diabetes Patients with Acute Kidney Disease Through Thiazolidinedione
Background: Diabetic patients are prone to acute kidney injury with the potential transition to
chronic kidney disease. We sought to investigate whether the use of thiazolidinedione …
chronic kidney disease. We sought to investigate whether the use of thiazolidinedione …
Exploring the Outcomes of SGLT2 Inhibitors in Diabetics Patients at Dialysis Commencement: A Health Global Federated Network Analysis
CA Wang, LC Lin, JY Chen, WJ Wang… - Li-Chun and Chen, Jui-Yi … - papers.ssrn.com
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of
antihyperglycemic medications with proven cardiovascular and kidney benefits. However …
antihyperglycemic medications with proven cardiovascular and kidney benefits. However …